
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17/7/2014
0:00
7:28
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Otros episodios de "GRACEcast Radiation Oncology Audio"



No te pierdas ningún episodio de “GRACEcast Radiation Oncology Audio”. Síguelo en la aplicación gratuita de GetPodcast.








